

# Myles A Brown

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6325796/myles-a-brown-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

275  
papers

44,579  
citations

98  
h-index

210  
g-index

361  
ext. papers

54,280  
ext. citations

14.8  
avg, IF

7.1  
L-index

#	Paper	IF	Citations
275	A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathway.. <i>IScience</i> , <b>2022</b> , 25, 104175	6.1	0
274	p16-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases.. <i>Nature Communications</i> , <b>2022</b> , 13, 1473	17.4	2
273	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.. <i>Nature Communications</i> , <b>2022</b> , 13, 2559	17.4	5
272	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 158-173	10.1	27
271	FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance. <i>Nature Cell Biology</i> , <b>2021</b> , 23, 1187-1198	23.4	2
270	Systematic characterization of mutations altering protein degradation in human cancers. <i>Molecular Cell</i> , <b>2021</b> , 81, 1292-1308.e11	17.6	11
269	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 1979	17.4	11
268	Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. <i>Nature Genetics</i> , <b>2021</b> , 53, 881-894	36.3	6
267	Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	4
266	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. <i>Nature Cancer</i> , <b>2021</b> , 2, 34-48	15.4	13
265	Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment. <i>Cancer Research</i> , <b>2021</b> , 81, 371-383	10.1	3
264	Integrin $\alpha$ 8-TGF $\beta$ SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. <i>Cancer Cell</i> , <b>2021</b> , 39, 54-67.e9	24.3	25
263	An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. <i>Cancer Cell</i> , <b>2021</b> , 39, 240-256.e11	24.3	29
262	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1524-1541	24.4	13
261	CoBRA: Containerized Bioinformatics Workflow for Reproducible ChIP/ATAC-seq Analysis. <i>Genomics, Proteomics and Bioinformatics</i> , <b>2021</b> ,	6.5	4
260	In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. <i>Cell</i> , <b>2021</b> , 184, 5357-5374.e22	56.2	15
259	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , <b>2021</b> , 36, 109665	10.6	4

258	Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells. <i>Cancer Letters</i> , <b>2021</b> , 519, 172-184	9.9	2
257	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 5775	17.4	6
256	Determinants of transcription factor regulatory range. <i>Nature Communications</i> , <b>2020</b> , 11, 2472	17.4	13
255	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 2350	17.4	15
254	CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma. <i>Genomics, Proteomics and Bioinformatics</i> , <b>2020</b> , 18, 26-40	6.5	6
253	The Dysregulated Pharmacology of Clinically Relevant Mutants is Normalized by Ligand-activated WT Receptor. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 1395-1405	6.1	11
252	Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. <i>Science Advances</i> , <b>2020</b> , 6, eabb2210	14.3	23
251	FiTAc-seq: fixed-tissue CHIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. <i>Nature Protocols</i> , <b>2020</b> , 15, 2503-2518	18.8	9
250	Lisa: inferring transcriptional regulators through integrative modeling of public chromatin accessibility and CHIP-seq data. <i>Genome Biology</i> , <b>2020</b> , 21, 32	18.3	60
249	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. <i>Molecular Cell</i> , <b>2020</b> , 78, 1096-1113.e8	17.6	35
248	Integrative analyses of single-cell transcriptome and regulome using MAESTRO. <i>Genome Biology</i> , <b>2020</b> , 21, 198	18.3	38
247	Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5990-6002	12.9	13
246	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. <i>Genome Biology</i> , <b>2020</b> , 21, 263	18.3	7
245	Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	12
244	ERG-Mediated Coregulator Complex Formation Maintains Androgen Receptor Signaling in Prostate Cancer. <i>Cancer Research</i> , <b>2020</b> , 80, 4612-4619	10.1	2
243	Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the NursesHealth Study II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 1264-1270	4	4
242	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. <i>Nature Communications</i> , <b>2019</b> , 10, 4358	17.4	50
241	Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. <i>Nature Protocols</i> , <b>2019</b> , 14, 756-780	18.8	79

240	Estrogen receptor signaling is reprogrammed during breast tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11437-11443	11.5	27
239	Consideration of breast cancer subtype in targeting the androgen receptor. <i>Pharmacology &amp; Therapeutics</i> , <b>2019</b> , 200, 135-147	13.9	35
238	Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5398-5406	12.9	29
237	LLGL2 rescues nutrient stress by promoting leucine uptake in ER breast cancer. <i>Nature</i> , <b>2019</b> , 569, 275-279.4	30.4	58
236	Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 30	8.3	37
235	Hormone-Responsive Cancers <b>2019</b> , 717-741.e8		1
234	A Bayesian model for single cell transcript expression analysis on MERFISH data. <i>Bioinformatics</i> , <b>2019</b> , 35, 995-1001	7.2	4
233	The Sly Oncogene: FOXA1 Mutations in Prostate Cancer. <i>Cancer Cell</i> , <b>2019</b> , 36, 119-121	24.3	6
232	The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. <i>Cell Reports</i> , <b>2019</b> , 29, 889-903.e10	10.6	17
231	Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers. <i>iScience</i> , <b>2019</b> , 21, 341-358	6.1	15
230	Abstract B077: Signatures of T-cell dysfunction and exclusion predict cancer immunotherapy response <b>2019</b> ,		4
229	BAG1L: a promising therapeutic target for androgen receptor-dependent prostate cancer. <i>Journal of Molecular Endocrinology</i> , <b>2019</b> , 62, R289-R299	4.5	6
228	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. <i>Cancer Cell</i> , <b>2019</b> , 35, 401-413.e6	24.3	74
227	Deciphering essential cistromes using genome-wide CRISPR screens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 25186-25195	11.5	16
226	FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> ,	11.5	46
225	Androgen Receptor Expression and Breast Cancer Survival: Results From the NursesHealth Studies. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 700-708	9.7	23
224	Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. <i>Nucleic Acids Research</i> , <b>2019</b> , 47, D729-D735	20.1	232
223	Pre-diagnostic sex hormone levels and survival among breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 174, 749-758	4.4	9

222	Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. <i>Molecular Cell</i> , <b>2018</b> , 69, 279-291.e5	17.6	91
221	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. <i>Cancer Cell</i> , <b>2018</b> , 33, 173-186.e5	24.3	133
220	Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies. <i>Cell Systems</i> , <b>2018</b> , 6, 343-354.e5	10.6	23
219	A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. <i>Science</i> , <b>2018</b> , 359, 770-775	33.3	404
218	Transcriptional Regulation in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2018</b> , 8,	5.4	34
217	Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 7869-7878	11.5	39
216	VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. <i>BMC Bioinformatics</i> , <b>2018</b> , 19, 135	3.6	80
215	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. <i>Nature Medicine</i> , <b>2018</b> , 24, 1550-1558	50.5	881
214	Unraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer. <i>Npj Breast Cancer</i> , <b>2018</b> , 4, 22	7.8	20
213	Enhancing Therapy: It's about Time. <i>Cell</i> , <b>2018</b> , 174, 771-772	56.2	
212	Differential impact of RB status on E2F1 reprogramming in human cancer. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 341-358	15.9	58
211	Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling. <i>Oncotarget</i> , <b>2018</b> , 9, 4282-4300	3.3	33
210	The SERM/SERD basedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. <i>ELife</i> , <b>2018</b> , 7,	8.9	42
209	Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-EREGREB1 Transcriptional Axis. <i>Cancer Research</i> , <b>2018</b> , 78, 671-684	10.1	59
208	KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. <i>Cancer Cell</i> , <b>2018</b> , 34, 939-953.e9	24.3	93
207	Androgen receptor expression in normal breast tissue and subsequent breast cancer risk. <i>Npj Breast Cancer</i> , <b>2018</b> , 4, 33	7.8	12
206	TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. <i>Cell Reports</i> , <b>2018</b> , 25, 1255-1267.e5	6.5	17
205	Improved design and analysis of CRISPR knockout screens. <i>Bioinformatics</i> , <b>2018</b> , 34, 4095-4101	7.2	21

204	A less invasive method for orthotopic injection of breast cancer cells into the mouse mammary gland. <i>Laboratory Animals</i> , <b>2017</b> , 51, 85-88	2.6	12
203	Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. <i>Science</i> , <b>2017</b> , 355, 78-83	33.3	492
202	Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. <i>Cell Reports</i> , <b>2017</b> , 18, 2359-2372	10.6	39
201	Vitamin D receptor regulates autophagy in the normal mammary gland and in luminal breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E2186-E2194	11.5	75
200	Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E4482-E4491	11.5	64
199	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E5207-E5215	11.5	155
198	The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer. <i>Current Oncology Reports</i> , <b>2017</b> , 19, 35	6.3	61
197	Transcriptional landscape of the human cell cycle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 3473-3478	11.5	67
196	Cistrome Cancer: A Web Resource for Integrative Gene Regulation Modeling in Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, e19-e22	10.1	89
195	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 7072-7083	12.9	61
194	Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. <i>Cancer</i> , <b>2017</b> , 123, 4130-4138	6.4	8
193	Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, T135-T145	5.7	29
192	Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. <i>Nucleic Acids Research</i> , <b>2017</b> , 45, D658-D662	20.1	265
191	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , <b>2017</b> , 1,	3.6	7
190	Role of steroid receptor and coregulator mutations in hormone-dependent cancers. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 1126-1135	15.9	32
189	Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006668	7.6	54
188	Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. <i>ELife</i> , <b>2017</b> , 6,	8.9	23
187	Modeling cis-regulation with a compendium of genome-wide histone H3K27ac profiles. <i>Genome Research</i> , <b>2016</b> , 26, 1417-1429	9.7	46

186	Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 10982	17.4	226
185	Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 1279-1286	44.5	269
184	An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine. <i>Scientific Reports</i> , <b>2016</b> , 6, 22120	4.9	11
183	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. <i>Cell Reports</i> , <b>2016</b> , 15, 2692-704	10.6	58
182	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1006-21	24.4	71
181	Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression. <i>Molecular Cancer Research</i> , <b>2016</b> , 14, 163-172	6.6	22
180	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. <i>Molecular Cancer Research</i> , <b>2016</b> , 14, 470-81	6.6	27
179	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. <i>Nature</i> , <b>2016</b> , 529, 413-417	50.4	363
178	Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	28
177	How drug resistance takes shape. <i>ELife</i> , <b>2016</b> , 5,	8.9	1
176	Overexpression of BCL9, a Wnt/ECatenin Transcriptional Co-Activator, in Transgenic Mice Promotes Spontaneous Development of B-Cell Malignancies. <i>Blood</i> , <b>2016</b> , 128, 441-441	2.2	
175	ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor. <i>ELife</i> , <b>2016</b> , 5,	8.9	44
174	ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline. <i>BMC Bioinformatics</i> , <b>2016</b> , 17, 404	3.6	72
173	High-dimensional genomic data bias correction and data integration using MANCIE. <i>Nature Communications</i> , <b>2016</b> , 7, 11305	17.4	28
172	TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. <i>Cancer Cell</i> , <b>2016</b> , 29, 846-858	24.3	160
171	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5755-5764	12.9	11
170	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , <b>2016</b> , 29, 574-586	24.3	154
169	Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. <i>Nature Medicine</i> , <b>2016</b> , 22, 685-91	50.5	44

168	FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E6600-E6609	11.5	91
167	ESR1 mutations: mechanism for acquired endocrine resistance in breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 573-83	19.4	313
166	PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. <i>Cancer Research</i> , <b>2015</b> , 75, 1944-8	10.1	40
165	Targeting the androgen receptor in breast cancer. <i>Current Oncology Reports</i> , <b>2015</b> , 17, 4	6.3	69
164	Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 962-8	4	14
163	Alcohol Consumption and Risk of Breast Cancer by Tumor Receptor Expression. <i>Hormones and Cancer</i> , <b>2015</b> , 6, 237-46	5	15
162	The androgen receptor cisome is extensively reprogrammed in human prostate tumorigenesis. <i>Nature Genetics</i> , <b>2015</b> , 47, 1346-51	36.3	226
161	Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 436-45	10.1	61
160	Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. <i>Cancer Discovery</i> , <b>2015</b> , 5, 72-81	24.4	106
159	TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. <i>Oncogene</i> , <b>2015</b> , 34, 3815-25	9.2	43
158	Sequence determinants of improved CRISPR sgRNA design. <i>Genome Research</i> , <b>2015</b> , 25, 1147-57	9.7	335
157	Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. <i>Genome Biology</i> , <b>2015</b> , 16, 281	18.3	171
156	Role of diet in prostate cancer: the epigenetic link. <i>Oncogene</i> , <b>2015</b> , 34, 4683-91	9.2	41
155	Long non-coding RNA-mediated PTEN regulation in prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16081-e16081	2.2	
154	Emergence of constitutively active estrogen receptor mutations in pretreated advanced estrogen receptor-positive breast cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1757-1767	12.9	415
153	Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy. <i>Current Breast Cancer Reports</i> , <b>2014</b> , 6, 71-78	0.8	12
152	XBP1 promotes triple-negative breast cancer by controlling the HIF1 $\alpha$ pathway. <i>Nature</i> , <b>2014</b> , 508, 103-107	70.4	512
151	Refined DNase-seq protocol and data analysis reveals intrinsic bias in transcription factor footprint identification. <i>Nature Methods</i> , <b>2014</b> , 11, 73-78	21.6	160



150	Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 2027-31	4	21
149	NF- $\kappa$ B activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 408-420	6.6	35
148	PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. <i>Cancer Discovery</i> , <b>2014</b> , 4, 1430-47	24.4	85
147	Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 7319-24	11.5	243
146	MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. <i>Oncogene</i> , <b>2014</b> , 33, 2790-800	9.2	114
145	Control of steroid receptor dynamics and function by genomic actions of the cochaperones p23 and Bag-1L. <i>Nuclear Receptor Signaling</i> , <b>2014</b> , 12, e005	1	15
144	MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. <i>Genome Biology</i> , <b>2014</b> , 15, 554	18.3	821
143	Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 8839-51	5.4	36
142	Research resource: Aorta- and liver-specific ER $\beta$ binding patterns and gene regulation by estrogen. <i>Molecular Endocrinology</i> , <b>2014</b> , 28, 1337-51		18
141	Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. <i>Cell Reports</i> , <b>2014</b> , 9, 1618-1627	10.6	82
140	Effect of HOXB13 and FOXA1 on the AR cistrome during prostate tumorigenesis in primary human tissue.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5018-5018	2.2	1
139	Residual estrogen receptor availability during fulvestrant 500 mg therapy in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 588-588	2.2	
138	Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing. <i>BMC Medical Genomics</i> , <b>2013</b> , 6, 21	3.7	19
137	Protein kinase C $\delta$ is a central signaling node and therapeutic target for breast cancer stem cells. <i>Cancer Cell</i> , <b>2013</b> , 24, 347-64	24.3	231
136	The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. <i>Cancer Cell</i> , <b>2013</b> , 24, 365-78	24.3	102
135	PET imaging of oestrogen receptors in patients with breast cancer. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, e465-475	4.75	134
134	D538G mutation in estrogen receptor- $\alpha$ a novel mechanism for acquired endocrine resistance in breast cancer. <i>Cancer Research</i> , <b>2013</b> , 73, 6856-64	10.1	279
133	Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. <i>Genome Biology</i> , <b>2013</b> , 14, R125	18.3	120

132	Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. <i>Cell</i> , <b>2013</b> , 152, 633-41	56.2	255
131	Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. <i>Nature Structural and Molecular Biology</i> , <b>2013</b> , 20, 908-13	17.6	432
130	PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. <i>Cancer Cell</i> , <b>2013</b> , 23, 753-67	24.3	45
129	CistromeFinder for ChIP-seq and DNase-seq data reuse. <i>Bioinformatics</i> , <b>2013</b> , 29, 1352-4	7.2	15
128	Amplitude modulation of androgen signaling by c-MYC. <i>Genes and Development</i> , <b>2013</b> , 27, 734-48	12.6	62
127	Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response. <i>PLoS ONE</i> , <b>2013</b> , 8, e64225	3.7	12
126	ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 1109-22	15.9	171
125	EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. <i>Science</i> , <b>2012</b> , 338, 1465-9	33.3	585
124	Elucidating the role of androgen receptor in breast cancer. <i>Clinical Investigation</i> , <b>2012</b> , 2, 1003-1011		11
123	Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. <i>Genome Research</i> , <b>2012</b> , 22, 1015-25	9.7	142
122	The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. <i>Prostate</i> , <b>2012</b> , 72, 1093-103	4.2	65
121	Tetradian oscillation of estrogen receptor $\beta$ s necessary to prevent liver lipid deposition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 11806-11	11.5	61
120	Estrogen receptor prevents p53-dependent apoptosis in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 18060-5	11.5	98
119	Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 576-576	2.2	1
118	Cistrome: an integrative platform for transcriptional regulation studies. <i>Genome Biology</i> , <b>2011</b> , 12, R83	18.3	461
117	PKA-dependent regulation of the histone lysine demethylase complex PHF2-ARID5B. <i>Nature Cell Biology</i> , <b>2011</b> , 13, 668-75	23.4	134
116	Targeting androgen receptor in estrogen receptor-negative breast cancer. <i>Cancer Cell</i> , <b>2011</b> , 20, 119-31	24.3	267
115	Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. <i>Cancer Cell</i> , <b>2011</b> , 20, 457-71	24.3	314

114	Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. <i>Molecular Endocrinology</i> , <b>2011</b> , 25, 1527-38		117
113	CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. <i>Cancer Research</i> , <b>2011</b> , 71, 528-37	10.1	99
112	BINOCh: binding inference from nucleosome occupancy changes. <i>Bioinformatics</i> , <b>2011</b> , 27, 1867-8	7.2	19
111	Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. <i>Cancer Research</i> , <b>2011</b> , 71, 6738-6748	10.1	71
110	GlcNAcylation of histone H2B facilitates its monoubiquitination. <i>Nature</i> , <b>2011</b> , 480, 557-60	50.4	233
109	E-catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis. <i>American Journal of Clinical Pathology</i> , <b>2011</b> , 135, 776-82	1.9	29
108	A comprehensive view of nuclear receptor cancer cistromes. <i>Cancer Research</i> , <b>2011</b> , 71, 6940-7	10.1	99
107	Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. <i>Genome Research</i> , <b>2011</b> , 21, 555-65	9.7	172
106	Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. <i>Molecular and Cellular Biology</i> , <b>2011</b> , 31, 226-36	4.8	99
105	Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 819-26	4.1	25
104	SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2565-73	2.2	134
103	Nucleosome dynamics define transcriptional enhancers. <i>Nature Genetics</i> , <b>2010</b> , 42, 343-7	36.3	382
102	Multimodal regulation of E2F1 gene expression by progestins. <i>Molecular and Cellular Biology</i> , <b>2010</b> , 30, 1866-77	4.8	23
101	TCF4 and CDX2, major transcription factors for intestinal function, converge on the same cis-regulatory regions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 15157-62	11.5	61
100	Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. <i>Genes and Development</i> , <b>2010</b> , 24, 2219-27	12.6	136
99	Estrogen-dependent and estrogen-independent mechanisms contribute to AIB1-mediated tumor formation. <i>Cancer Research</i> , <b>2010</b> , 70, 4102-11	10.1	40
98	MYC regulation of a "poor-prognosis" metastatic cancer cell state. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 3698-703	11.5	134
97	8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 9742-6	11.5	295

96	Differentiation-specific histone modifications reveal dynamic chromatin interactions and partners for the intestinal transcription factor CDX2. <i>Developmental Cell</i> , <b>2010</b> , 19, 713-26	10.2	156
95	Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. <i>American Journal of Pathology</i> , <b>2010</b> , 176, 2139-49	5.8	36
94	Genome Wide DNA Methylation Profiling In Patients with Multiple Myeloma.. <i>Blood</i> , <b>2010</b> , 116, 3622-3622		
93	Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2010</b> , 116, 3620-3620		
92	Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 4260-5	11.5	316
91	Combining chromatin immunoprecipitation and oligonucleotide tiling arrays (ChIP-Chip) for functional genomic studies. <i>Methods in Molecular Biology</i> , <b>2009</b> , 556, 155-64	1.4	3
90	Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. <i>Molecular Endocrinology</i> , <b>2009</b> , 23, 1385-96		51
89	Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery. <i>Genome Research</i> , <b>2009</b> , 19, 1963-73	9.7	108
88	Cistromics of hormone-dependent cancer. <i>Endocrine-Related Cancer</i> , <b>2009</b> , 16, 381-9	5.7	69
87	FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3680-92.9		68
86	Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. <i>Cancer Research</i> , <b>2009</b> , 69, 3140-7	10.1	21
85	Coactivator function defines the active estrogen receptor alpha cistrome. <i>Molecular and Cellular Biology</i> , <b>2009</b> , 29, 3413-23	4.8	65
84	Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. <i>Cancer Cell</i> , <b>2009</b> , 16, 413-24	24.3	102
83	Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. <i>Cell</i> , <b>2009</b> , 138, 245-56	56.2	691
82	Estradiol-regulated microRNAs control estradiol response in breast cancer cells. <i>Nucleic Acids Research</i> , <b>2009</b> , 37, 4850-61	20.1	270
81	The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. <i>Cancer Research</i> , <b>2009</b> , 69, 3356-63	10.1	211
80	Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers. <i>Genome Research</i> , <b>2009</b> , 19, 372-80	9.7	83
79	Mapping the Androgen Receptor Cistrome <b>2009</b> , 663-680		

78	Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. <i>Nature</i> , <b>2008</b> , 456, 663-6	50.4	242
77	Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. <i>EMBO Journal</i> , <b>2008</b> , 27, 535-45	13	240
76	xMAN: extreme MApping of OligoNucleotides. <i>BMC Genomics</i> , <b>2008</b> , 9 Suppl 1, S20	4.5	17
75	Model-based analysis of CHIP-Seq (MACS). <i>Genome Biology</i> , <b>2008</b> , 9, R137	18.3	8406
74	FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. <i>Cell</i> , <b>2008</b> , 132, 958-70	56.2	746
73	AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. <i>Molecular and Cellular Biology</i> , <b>2008</b> , 28, 7487-503	4.8	82
72	Unraveling estrogen action in osteoporosis. <i>Cell Cycle</i> , <b>2008</b> , 7, 1348-52	4.7	41
71	CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. <i>Cancer Research</i> , <b>2008</b> , 68, 3204-13	10.1	151
70	Nkx3-1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity. <i>Cancer Research</i> , <b>2008</b> , 68, 7380-5	10.1	35
69	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 815-25	9.7	251
68	Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. <i>Genome Research</i> , <b>2008</b> , 18, 393-403	9.7	111
67	Unique ERalpha cistromes control cell type-specific gene regulation. <i>Molecular Endocrinology</i> , <b>2008</b> , 22, 2393-406		110
66	Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. <i>Molecular Endocrinology</i> , <b>2008</b> , 22, 2420-32		28
65	CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. <i>Cancer Research</i> , <b>2008</b> , 68, 301-6	10.1	156
64	Targeting NF-kappaB in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2008</b> , 111, 5068-77	2.2	92
63	Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. <i>Prostate</i> , <b>2008</b> , 68, 839-48	4.2	59
62	The OXR domain defines a conserved family of eukaryotic oxidation resistance proteins. <i>BMC Cell Biology</i> , <b>2007</b> , 8, 13		55
61	Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. <i>Cancer Research</i> , <b>2007</b> , 67, 6477-83	10.1	274

60	A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. <i>Molecular Cell</i> , <b>2007</b> , 27, 380-92	17.6	526
59	X chromosomal abnormalities in basal-like human breast cancer. <i>Cancer Cell</i> , <b>2006</b> , 9, 121-32	24.3	649
58	The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. <i>Carcinogenesis</i> , <b>2006</b> , 27, 599-605	4.6	29
57	Estrogen receptor target gene: an evolving concept. <i>Molecular Endocrinology</i> , <b>2006</b> , 20, 1707-14		210
56	A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. <i>Genes and Development</i> , <b>2006</b> , 20, 2513-26	12.6	223
55	Model-based analysis of tiling-arrays for ChIP-chip. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 12457-62	11.5	375
54	Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. <i>Cancer Research</i> , <b>2006</b> , 66, 11381-8	10.1	44
53	Primate-specific evolution of an LDLR enhancer. <i>Genome Biology</i> , <b>2006</b> , 7, R68	18.3	15
52	p63 regulates an adhesion programme and cell survival in epithelial cells. <i>Nature Cell Biology</i> , <b>2006</b> , 8, 551-61	23.4	330
51	Genome-wide analysis of estrogen receptor binding sites. <i>Nature Genetics</i> , <b>2006</b> , 38, 1289-97	36.3	1115
50	Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. <i>Journal of Urology</i> , <b>2005</b> , 173, 1772-7	2.5	82
49	Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. <i>Molecular Cell</i> , <b>2005</b> , 19, 631-42	17.6	372
48	Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. <i>Cell</i> , <b>2005</b> , 122, 33-43	56.2	1084
47	Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. <i>Molecular Endocrinology</i> , <b>2005</b> , 19, 1543-54		93
46	Modulator recognition factor 1, an AT-rich interaction domain family member, is a novel corepressor for estrogen receptor alpha. <i>Molecular Endocrinology</i> , <b>2005</b> , 19, 2491-501		24
45	Coactivator AIB1 links estrogen receptor transcriptional activity and stability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 11599-604	11.5	108
44	High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. <i>Cancer Cell</i> , <b>2004</b> , 6, 263-74	24.3	315
43	Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. <i>Breast Cancer Research</i> , <b>2004</b> , 6, 39-52	8.3	141

42	Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 7920-5	4.8	124
41	ERAP140, a conserved tissue-specific nuclear receptor coactivator. <i>Molecular and Cellular Biology</i> , <b>2002</b> , 22, 3358-72	4.8	82
40	Molecular determinants for the tissue specificity of SERMs. <i>Science</i> , <b>2002</b> , 295, 2465-8	33.3	987
39	Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. <i>Urology</i> , <b>2002</b> , 60, 1-6	1.6	24
38	Formation of the androgen receptor transcription complex. <i>Molecular Cell</i> , <b>2002</b> , 9, 601-10	17.6	556
37	Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. <i>Cancer Research</i> , <b>2002</b> , 62, 89-98	10.1	86
36	Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein. <i>Genes and Development</i> , <b>2001</b> , 15, 2598-612	12.6	87
35	Target-directed enediynes: designed estramycins. <i>Journal of Organic Chemistry</i> , <b>2001</b> , 66, 3688-95	4.2	38
34	Amplified in Breast Cancer-1 Glutamine Repeat and Prostate Cancer Risk. <i>Prostate Journal</i> , <b>2000</b> , 2, 27-32		11
33	BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. <i>Molecular and Cellular Biology</i> , <b>2000</b> , 20, 7541-9	4.8	196
32	Specific association of estrogen receptor beta with the cell cycle spindle assembly checkpoint protein, MAD2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 2836-9	11.5	55
31	AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. <i>Molecular and Cellular Biology</i> , <b>2000</b> , 20, 5041-7	4.8	383
30	Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. <i>Cell</i> , <b>2000</b> , 103, 843-52	56.2	1472
29	Polymorphic repeat in AIB1 does not alter breast cancer risk. <i>Breast Cancer Research</i> , <b>2000</b> , 2, 378-85	8.3	17
28	Protein-degrading enediynes: library screening of Bergman cycloaromatization products. <i>Organic Letters</i> , <b>2000</b> , 2, 1863-6	6.2	41
27	Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. <i>Journal of Endocrinology</i> , <b>1999</b> , 162, 137-42	4.7	154
26	Segregation of steroid receptor coactivator-1 from steroid receptors in mammary epithelium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1999</b> , 96, 208-13	11.5	58
25	Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. <i>American Journal of Human Genetics</i> , <b>1999</b> , 64, 1371-7	11	196

24	Functional Analysis of a Novel Estrogen Receptor- $\alpha$ Isoform. <i>Molecular Endocrinology</i> , <b>1999</b> , 13, 129-137		73
23	The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>1998</b> , 1378, C1-5	11.2	8
22	Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). <i>Molecular Endocrinology</i> , <b>1998</b> , 12, 1551-7		128
21	Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. <i>Molecular and Cellular Biology</i> , <b>1997</b> , 17, 5338-47	4.8	339
20	The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1997</b> , 94, 3320-3	11.5	668
19	Human Estrogen Receptor (ER) Gene Promoter-P1: Estradiol-Independent Activity and Estradiol Inducibility in ER+ and ER- Cells. <i>Molecular Endocrinology</i> , <b>1997</b> , 11, 1319-1331		25
18	Location of BRCA1 in human breast and ovarian cancer cells. <i>Science</i> , <b>1996</b> , 272, 123-6	33.3	204
17	p300 is a component of an estrogen receptor coactivator complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1996</b> , 93, 11540-5	11.5	324
16	Polarity-specific activities of retinoic acid receptors determined by a co-repressor. <i>Nature</i> , <b>1995</b> , 377, 451-4	50.4	511
15	Differential activation of peroxisome proliferator-activated receptors by eicosanoids. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 23975-83	5.4	548
14	Estrogen Receptor Molecular Biology. <i>Hematology/Oncology Clinics of North America</i> , <b>1994</b> , 8, 101-112	3.1	21
13	Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. <i>Science</i> , <b>1994</b> , 264, 1455-8	33.3	570
12	Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1991</b> , 88, 683-7	11.5	202
11	lac repressor can regulate expression from a hybrid SV40 early promoter containing a lac operator in animal cells. <i>Cell</i> , <b>1987</b> , 49, 603-12	56.2	137
10	SV40 small t antigen enhances the transformation activity of limiting concentrations of SV40 large T antigen. <i>Cell</i> , <b>1987</b> , 48, 321-30	56.2	135
9	Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. <i>Cell</i> , <b>1985</b> , 41, 49-56	56.2	142
8	Modification of SV40 T antigen by poly ADP-ribosylation. <i>Cell</i> , <b>1981</b> , 24, 567-72	56.2	113
7	Data Integration on Noncoding RNA Studies403-424		



6	Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer	2
5	CoBRA: Containerized Bioinformatics workflow for Reproducible CHIP/ATAC-seq Analysis - from differential peak calling to pathway analysis	3
4	Inferring transcriptional regulators through integrative modeling of public chromatin accessibility and CHIP-seq data	1
3	Integrative analysis and refined design of CRISPR knockout screens	1
2	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets	1
1	CHIPS: A Snakemake pipeline for quality control and reproducible processing of chromatin profiling data. <i>F1000Research</i> ,10, 517	3.6 0